SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Impax Laboratories, Inc. – IPXL

By , in PR PR Los Angeles on .

NEW YORK, Dec. 1, 2017 — Pomerantz LLP is investigating claims on behalf of investors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ:   IPXL).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, Ext. 9980.

Pomerantz announces an investigation into possible breaches of fiduciary duties by the Impax board of directors in connection with the proposed all-stock-merger of Impax with Amneal Pharmaceuticals LLC, in which Impax shareholders will own 25% of the new company's shares and Amneal Holdings members will own 75%.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
[email protected]

View original content:–ipxl-300565408.html

SOURCE Pomerantz LLP

Related Links

The following two tabs change content below.
Sarah Thompson

Sarah Thompson

Sarah is a financial reporter, focusing on technology, national security, and policing. Before joining Daily Telescope she worked as a staff writer at Fast Company and spent two years as a foreign correspondent in Turkey. Her work has been published in Al Jazeera America, The Nation, Vice News, Motherboard, and many other outlets.
%d bloggers like this: